Rescue Studies

RAPID ASSIST Rescue Services
Considering the diversity of our country and India's unique regulatory and demographic environment, Neeman Clinical Research can help you to achieve your vision with its mission of providing quality delivery of service to both external and internal customers. Fast Rescue Study Start-up
A new initiative of the Indian regulatory authority makes it possible to start your study in India within 6 weeks. This directive applies to any study that is currently approved and under way in the United States, the European Union, Japan, or another major country. Access to Thousands of Patients
With a population exceeding 1 billion people and a well developed healthcare infrastructure, India has plenty of patients in virtually all therapeutic areas and indications. In particular, India has a high prevalence of diabetes, cardiovascular disease, hepatitis, cancer, CNS indications, and infectious diseases. For most diseases the standard of care is inline with the Western countries, including the same diagnostic tools and drugs. Still, because of lower health awareness, many "treatment-naïve" patients can also be found in all indications. Subpopulations that are rare in the United States, such as patients with unresectable tumors, may be accessed in India. Neeman CR works with approximately 250 GCP investigators encompassing all the indications listed. For chronic diseases, these sites maintain active patient databases. FDA-Quality DataSince 2001, Neeman CR has managed more than 70 Phase I-IV clinical trials for international companies ranging from small Biotech to large Pharmaceutical industry. More than 50 of these clinical trials contributed Indian data to FDA submissions. In many of them Neeman CR provided the recruitment boost required to complete the study.